van der Meer PF, et al. - Researchers compared the effectiveness of pathogen inactivated platelets using riboflavin and ultraviolet B illumination technology (intervention) vs standard plasma-stored platelets (control) for the prevention of bleeding in patients with hematologic malignancies and thrombocytopenia in a randomized noninferiority trial. Findings suggested that the intention-to-treat analysis met the noninferiority criterion for pathogen inactivated platelets. In the per-protocol analysis, this finding was not demonstrated. About 50% lower transfusion increment parameters were seen in the intervention arm. The patients developing HLA class I alloantibodies demonstrated no difference in the proportion.